tumor activity Articles
-
Anaphase-promoting complex/cyclosome-cdh1-mediated proteolysis of the forkhead box m1 transcription factor is critical for regulated entry into s phase
The forkhead box M1 (FoxM1) transcription factor is overexpressed in many cancers, and in mouse models it is required for tumor progression. FoxM1 activates expression of the cell cycle genes required for both S and M phase progression. Here we demonstrate that FoxM1 is degraded in late mitosis and early G1 phase by the anaphase-promoting complex/cyclosome (APC/C) E3 ubiquitin ligase. FoxM1 ...
-
Potent anti-tumor activity against patient CLL, MM and AML cells by LAVA-051, a bispecific Vγ9Vδ2-T and type 1 NKT cell engager targeting CD1d
Bispecific antibodies that target tumors by engaging innate-like T cell subsets with inherent antitumor activity Bispecific antibodies that target tumors by engaging innate-like T cell subsets with inherent antitumor activity CD1d can be expressed by several hematologic malignancies Bispecific Vγ9Vδ2-T cell engager Unique ability to also trigger type 1 natural killer T (NKT) ...
-
Development Trends And Potential Challenges of PROTACs
PROTAC technology has been in development for more than 20 years. PROTAC proof-of-concept studies date back to 2001, when Crews' team tested the possibility of artificially induced intracellular protein degradation with a peptide that was too large in molecular weight and required cells to penetrate the peptide to improve cell permeability. The discovery of the first small molecule PROTAC and the ...
-
Review of ADC Linker and Research Progress
The linker is not only the molecule part of the covalent link between the antibody and the small molecule payload, but also a key element with design properties in targeted drug therapy. The addition of the linker should not induce aggregation and needs to ensure acceptable PK characteristics, while limiting the premature release of the payload in plasma and enabling the effective release of ...
By BOC Sciences
-
Science: Knockout of this epigenetic gene gives CAR-T cells the ability to continuously attack cancer cells
Simply put, CAR-T is to transform the patient's immune T cells in vitro by biotechnology, so that they recognize antigens on the surface of tumor cells, and then inject these cells back into the patient to achieve the therapeutic effect of recognizing and killing cancer cells. In 2017, CAR-T therapy was first approved by the FDA for the treatment of blood cancers such as leukemia and lymphoma. ...
-
Modulation of anti-tumour functions of NK cells and macrophages after single low-level exposures of mice to X-rays
Based on the reports suggesting that exposures to low doses of ionising radiation may impede tumour development and/or trigger the activity of natural anti-neoplastic defence mechanisms we demonstrate in the present study that single whole-body irradiations of mice with 0.1 or 0.2 Gy X-rays significantly decreased the number of the induced tumour colonies in the lungs and that the effect was ...
-
Bispecific Antibodies and Bispecific Antibody ADCs
With the rapid development of antibody-drug conjugate (ADC), more and more companies have entered the field of ADC research and development, and various types of ADC technologies and branches have emerged. Bispecific antibody conjugates (BsAb ADCs) are one of the emerging new technologies. The high specificity of bispecific antibodies enables more precise targeting of tumor cells. On the other ...
By BOC Sciences
-
Single or fractionated irradiations of mice with low doses of X-rays stimulate innate immune mechanisms
Single and fractionated Whole-Body Irradiation (WBI) of the BALB/c mice with total doses of 0.1 or 0.2 Gy X-rays led to reductions in the number of pulmonary tumour colonies. Single and fractionated WBI with 0.1 or 0.2 Gy, as well as the fractionated exposure to 1.0 Gy X-rays, significantly stimulated: the cytotoxicity of macrophages (Mφ) and Natural Killer (NK) cells mediated mainly by ...
-
What are the Possibilities for ADCs Targeting Trop2?
Antibody drug conjugate (ADC) research involves more and more targets, such as HER-2, Trop-2, Claudin-18.2, B7-H3 and B7-H4, etc. Trop-2 is a transmembrane glycoprotein. Its high expression is associated with the occurrence of many tumors and poor prognosis. It is a very popular ADC research target, second only to HER2. Currently, only Gilead's Trop-2 ADC drug Trodelvy has been approved for ...
By BOC Sciences
-
Research Progress of Tetrahydrocurcumin
Tetrahydrocurcumin (THC), as the most active and main metabolite produced in the metabolism of curcumin in vivo, can be isolated from the cytoplasm of the small intestine and liver after curcumin administration in human or mouse. Tetrahydrocurcumin can effectively inhibit tyrosinase, inhibit the generation of Oxygen Free Radicals and scavenge the formed free radicals. It has obvious antioxidant ...
-
Recent Advances in ADC Linker
The development of antibody-drug conjugates (ADCs) has progressed significantly over the past decade due to improvements in payloads, linkers, and conjugation methods. In particular, linker design plays a key role in regulating ADC stability in systemic circulation and payload release efficiency in tumors, thereby affecting ADC pharmacokinetics (PK), efficacy, and toxicity profiles. Some key ...
By BOC Sciences
-
Revealing the molecular mechanism of mutant protein-induced melanoma in the body
The RNA surveillance pathway detects and interprets defective transcripts to ensure RNA fidelity. Recently, in a research report entitled "Oncogenic CDK13 mutations impede nuclear RNA surveillance" published in Science, scientists from Howard Hughes Medical Institute and other institutions discovered a new type of mechanism that affects the occurrence of melanoma, providing broad and important ...
-
The nanovaccine technology with huge potentials
Vaccines are an unparalleled medical milestone that has saved countless lives by harnessing the human immune system, according to the history of human development. Vaccine remains the most effective source of defense against the COVID-19 pandemic since 2020. The success of the lipid nanoparticle COVID-19 mRNA vaccine shows that nanotechnology can be used in vaccine development. Compared to ...
-
Gamma delta T cells in tumor immunotherapy
Immunotherapy, in addition to surgery, chemotherapy, and radiotherapy, has now become the fourth pillar of anticancer treatment, with T cell-based immunotherapy being a successful cancer treatment technique. T cells can be separated into two subpopulations based on the expression of T-cell receptors (TCRs). αβ T cells, expressing expressing αβ TCR, recognize peptide antigens, such as those ...
-
Antibody-peptide epitope conjugate (APEC), another disguise for ADC
Background Tumor immunotherapies compose immune checkpoint inhibitors, therapeutic antibodies, tumor vaccines, cellular therapies, and so on. However, each has its own set of issues, such as the fact that CAR-T therapy is an individual therapy that is costly; immune checkpoint inhibitors are highly effective, but only in some patients. The researchers expose us to a radically different way of ...
-
The enhancement of Th1 immunity and the suppression of tumour growth by low-dose γ-radiation
To address if the modulation of immunity balance by low dose radiation is involved in the enhancement of the anti-tumour function, we examined the effect of 0.5 Gy γ-irradiation on the Th1/Th2 immunity balance in Ehrlich Solid Tumour (EST)-bearing mice. Repeated 0.5 Gy γ-irradiation significantly delayed the growth of tumours. The cytotoxic activities of Natural Killer (NK) cells and Cytotoxic T ...
-
Based on Antibody Targeted Protein Degradation
In recent years, PROteolysis TArgeting Chimeras (PROTAC), which utilizes the cell's own degradation mechanisms to eliminate specific disease-related proteins, has emerged as one of the most promising methods. Apart from PROTAC, various targeted protein degradation (TPD) strategies are emerging, involving molecular glue, Autophagy-Targeting Chimera (AUTEC), Autophagosome Tethering Compound ...
By BOC Sciences
-
Antibody-Drug Conjugates: New Strategies of ADC Payloads
The concept of ADCs was first proposed by Nobel Prize winner Paul Ehrlich in 1913. But it was not until 1975, when hybridoma technology began to be used to produce monoclonal antibodies, that the era of ADC drug development truly began. Driven by increasingly mature technology, ADC drugs have gone through three iterations (Fig. 1). Although ADCs have gone through three iterations, current ...
By BOC Sciences
-
Augmentation of anti–tumour activity of cisplatin by pectin nano–conjugates in B–16 mouse model: pharmacokinetics and in–vivo biodistribution of radio–labelled, hydrophilic nano–conjugates
Nanoconjugates have matured from simple devices to multifunctional, biodegradable, non–toxic and non–immunogenic constructs, capable of delivering synergistically functioning drugs in vivo. The present study evaluates the efficacy of drug polymer self folding nano–conjugates of pectin–cisplatin to enhance blood circulating levels of cisplatin. Physical characterisation was done by DLS, zeta ...
-
How to Design a Good ADC Drug
In the past ten years, the number of antibody drug conjugates (ADCs) entering clinical trials has steadily increased. Currently, 9 ADCs have been approved, of which 5 are used for hematoma and 4 for solid tumor treatment. After more than 20 years of development, ADC biopharmaceuticals are becoming the main force in the treatment of cancer. Currently, one of the most important challenges when ...
By BOC Sciences
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you